Capstan Therapeutics
Capstan Therapeutics is dedicated to developing transformative RNA therapies using their proprietary CellSeeker™ targeted lipid nanoparticle platform. Their mission is to harness in vivo delivery of disease-modifying RNA payloads to reprogram target cells, with a focus on autoimmune disorders, oncology, and fibrosis. They aim to create scalable, safe, and accessible therapies that can make a significant impact on patient care.
Industries
Nr. of Employees
medium (51-250)
Capstan Therapeutics
Patents
Products
Targeted lipid nanoparticle delivery platform
A modular targeted LNP platform composed of biodegradable lipid nanoparticles conjugated with targeting binders to deliver RNA payloads (mRNA or gene-editing reagents) to specific cell types in vivo.
CPTX2309 (CD19) — in vivo CAR-T program
Clinical-stage program using CD8-targeted LNPs to deliver mRNA encoding an anti–CD19 CAR to CD8-expressing T cells for treatment of B cell–mediated autoimmune disease.
CPTX2506 (BCMA) — discovery-stage program
Discovery-stage program targeting BCMA for plasma cell disorders using targeted LNP delivery of RNA payloads.
Fibroblast-targeted discovery programs
Discovery-stage programs focused on delivering RNA payloads to fibroblasts for immunology, oncology, and fibrotic indications.
Additional discovery-stage in vivo RNA programs
Undisclosed discovery-stage programs applying targeted LNP delivery to additional indications beyond listed programs.
Targeted lipid nanoparticle delivery platform
A modular targeted LNP platform composed of biodegradable lipid nanoparticles conjugated with targeting binders to deliver RNA payloads (mRNA or gene-editing reagents) to specific cell types in vivo.
CPTX2309 (CD19) — in vivo CAR-T program
Clinical-stage program using CD8-targeted LNPs to deliver mRNA encoding an anti–CD19 CAR to CD8-expressing T cells for treatment of B cell–mediated autoimmune disease.
CPTX2506 (BCMA) — discovery-stage program
Discovery-stage program targeting BCMA for plasma cell disorders using targeted LNP delivery of RNA payloads.
Fibroblast-targeted discovery programs
Discovery-stage programs focused on delivering RNA payloads to fibroblasts for immunology, oncology, and fibrotic indications.
Additional discovery-stage in vivo RNA programs
Undisclosed discovery-stage programs applying targeted LNP delivery to additional indications beyond listed programs.
Services
Engagements for research collaborations, business development partnerships, and data-sharing related to in vivo RNA delivery and targeted LNP programs.
Engagements for research collaborations, business development partnerships, and data-sharing related to in vivo RNA delivery and targeted LNP programs.
Expertise Areas
- In vivo CAR-T therapy development
- RNA therapeutics and mRNA delivery
- Targeted lipid nanoparticle (LNP) engineering
- In vivo gene editing delivery to HSPCs and T cells
Key Technologies
- Lipid nanoparticles (LNPs)
- mRNA therapeutics
- Gene-editing payloads
- Antibody/ligand-mediated targeting